Rosanna Pe Chow, MD
Family Practice · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 50 years
- Graduated 1976
Offices
1 location
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus · UCSF Health Stanyan Hospital. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chow’s office at (415) 387-8031 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- UCSF Health St. Mary'S HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for UCSF Health St. Mary'S Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 413 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.58 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 146.74 (92.54 to 200.93) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 51 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.3 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 102 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,363 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 2,530 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.12 to 0.53) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.02 (0.73 to 5.31) · 590 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.35) · 238 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (0.43 to 3.7) · 554 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.7 (4.19 to 21.21) · 259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.67 (1.51 to 9.83) · 203 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.99) · 2,258 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 158 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 61 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 291 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.4 · 251 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 5.5 · 189 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 213 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.5) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12 (8.3 to 17.1) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 176 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.8) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 113 cases | No different | Jan 2024 – Dec 2024 |
What patients said (587 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$7,509
Medicare paid this office $7,509 for 36 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $3,737 | $156 |
| Return visit (30+ min) | 11 | $1,675 | $88 |
| Short return visit (20+ min) | 20 | $1,658 | $52 |
Who their Medicare patients are
36 Original Medicare patients in 2024. Average age 76 · Women 69% · Health risk score 0.57. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 50%.
The office billed $15,596, Medicare allowed $10,750 and paid $7,509; for 80 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 36 | 80 | 76 | 0.57 | $15,596 | $7,509 |
| 2023 | 37 | 92 | 76 | 0.63 | $15,880 | $9,645 |
| 2022 | 42 | 99 | 75 | 0.74 | $15,064 | $8,675 |
| 2021 | 36 | 70 | 76 | 0.75 | $10,813 | $7,371 |
| 2020 | 45 | 102 | 74 | 0.88 | $15,868 | $8,299 |
| 2019 | 113 | 260 | 73 | 0.79 | $41,775 | $18,212 |
| 2018 | 133 | 323 | 73 | 0.84 | $49,200 | $21,589 |
| 2017 | 152 | 342 | 72 | 0.78 | $48,183 | $22,785 |
| 2016 | 111 | 342 | 73 | 0.77 | $52,456 | $26,460 |
| 2015 | 58 | 101 | 72 | 0.96 | $16,104 | $7,208 |
| 2014 | 112 | 338 | 73 | 0.81 | $42,992 | $20,922 |
| 2013 | 79 | 280 | 74 | 0.83 | $38,181 | $17,826 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $4,435 | $153 |
| Short return visit (20+ min) | 20 | $2,672 | $76 |
| Return visit (30+ min) | 15 | $2,360 | $94 |
2022: 3 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $3,695 | $154 |
| Short return visit (20+ min) | 26 | $2,167 | $53 |
| Return visit (30+ min) | 16 | $2,000 | $87 |
2021: 2 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $3,762 | $157 |
| Short return visit (20+ min) | 19 | $2,269 | $73 |
2020: 3 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 21 | $2,944 | $140 |
| Short return visit (20+ min) | 30 | $2,498 | $54 |
| Return visit (30+ min) | 14 | $1,708 | $85 |
2019: 3 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 38 | $5,302 | $140 |
| Short return visit (20+ min) | 70 | $4,451 | $49 |
| Return visit (30+ min) | 35 | $2,933 | $72 |
2018: 6 services
| Short return visit (20+ min) | 80 | $4,913 | $50 |
| Return visit (30+ min) | 38 | $3,409 | $74 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $3,319 | $138 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 12 | $1,914 | $159 |
| Influenza vaccine split virus, preservative free | 29 | $1,552 | $52 |
| Administration of influenza virus vaccine | 28 | $733 | $25 |
2017: 7 services
| Short return visit (20+ min) | 72 | $4,866 | $54 |
| Return visit (30+ min) | 53 | $4,650 | $75 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 27 | $3,741 | $139 |
| Pneumococcal vaccine, 13-valent | 13 | $2,432 | $187 |
| Influenza vaccine split virus, preservative free | 31 | $1,477 | $48 |
| Administration of influenza virus vaccine | 31 | $1,003 | $32 |
| Administration of pneumococcal vaccine | 17 | $550 | $32 |
2016: 8 services
| Return visit (30+ min) | 49 | $6,029 | $90 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 38 | $5,310 | $140 |
| Short return visit (20+ min) | 56 | $4,669 | $52 |
| Pneumococcal vaccine, 13-valent | 26 | $4,590 | $177 |
| New patient visit (30+ min) | 14 | $1,265 | $90 |
| Influenza vaccine split virus, preservative free | 23 | $923 | $38 |
| Administration of pneumococcal vaccine | 25 | $810 | $32 |
| Administration of influenza virus vaccine | 21 | $713 | $32 |
2015: 2 services
| Return visit (30+ min) | 25 | $2,004 | $72 |
| Short return visit (20+ min) | 21 | $1,449 | $60 |
2014: 8 services
| Short return visit (20+ min) | 65 | $5,755 | $58 |
| Return visit (30+ min) | 38 | $4,444 | $84 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 22 | $2,998 | $136 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 12 | $2,403 | $200 |
| Administration of influenza virus vaccine | 32 | $1,013 | $32 |
| Influenza vaccine split virus, preservative free | 28 | $903 | $32 |
| New patient visit (15+ min) | 11 | $566 | $51 |
| Manual urinalysis test with examination using microscope, non-automated | 18 | $89 | $4 |
2013: 6 services
| Return visit (30+ min) | 38 | $5,305 | $87 |
| Short return visit (20+ min) | 43 | $3,994 | $53 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 21 | $2,826 | $135 |
| Administration of influenza virus vaccine | 19 | $618 | $33 |
| Influenza vaccine split virus, preservative free | 19 | $586 | $31 |
| Manual urinalysis test with examination using microscope, non-automated | 11 | $51 | $4 |
Drugs they prescribed that Part D paid
$40,687
Pharmacies billed $40,687 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
796 generic and fewer than 11 brand-name prescriptions · $40,687 in drug cost · 23 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Losartan | 81 | $928 | $11 |
| Atorvastatin | 80 | $782 | $10 |
| Levothyroxine | 44 | $542 | $12 |
| Metformin | 65 | $456 | $7 |
| Amlodipine Besylate | 56 | $452 | $8 |
See all 17 drugs
| Losartan | 81 | $928 | $11 |
| Atorvastatin | 80 | $782 | $10 |
| Levothyroxine | 44 | $542 | $12 |
| Metformin | 65 | $456 | $7 |
| Amlodipine Besylate | 56 | $452 | $8 |
| Metoprolol | 18 | $440 | $24 |
| Fenofibrate | 16 | $435 | $27 |
| Carvedilol | 21 | $299 | $14 |
| Lovastatin | 52 | $294 | $6 |
| Gabapentin | 35 | $288 | $8 |
| Alendronate | 34 | $173 | $5 |
| Benazepril | 11 | $155 | $14 |
| Simvastatin | 42 | $139 | $3 |
| Trazodone | 15 | $106 | $7 |
| Fluoxetine | 17 | $104 | $6 |
| Lisinopril | 23 | $100 | $4 |
| Fluticasone Propionate | 15 | $93 | $6 |
Year by year
| 2024 | 865 | 97 | None | None | $40,687 |
| 2023 | 658 | 85 | None | 6% | $24,529 |
| 2022 | 596 | 73 | 0% (0) | None | $19,007 |
| 2021 | 589 | 79 | None | 5% | $18,861 |
| 2020 | 802 | 89 | None | 8% | $30,890 |
| 2019 | 920 | 122 | 0% (0) | 10% | $41,948 |
| 2018 | 931 | 128 | None | 11% | $36,087 |
| 2017 | 934 | 122 | None | None | $40,702 |
| 2016 | 1,023 | 111 | 1% (12) | None | $41,232 |
| 2015 | 910 | 103 | 2% (14) | 19% | $38,580 |
| 2014 | 1,045 | 108 | 2% (20) | None | $47,049 |
| 2013 | 1,122 | 97 | 3% (28) | None | $51,271 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Losartan | 67 | $949 | $14 |
| Lovastatin | 53 | $828 | $16 |
| Atorvastatin | 66 | $797 | $12 |
| Metformin | 58 | $636 | $11 |
| Amlodipine Besylate | 56 | $558 | $10 |
| Levothyroxine | 33 | $521 | $16 |
| Simvastatin | 21 | $400 | $19 |
| Carvedilol | 22 | $291 | $13 |
| Lisinopril | 26 | $266 | $10 |
| Alendronate | 20 | $254 | $13 |
| Triamcinolone Acetonide | 12 | $187 | $16 |
| Paxlovid (Eua) | 11 | $112 | $10 |
| Fluoxetine | 12 | $95 | $8 |
2022: 14 drugs
| Losartan | 67 | $1,027 | $15 |
| Atorvastatin | 52 | $729 | $14 |
| Lovastatin | 48 | $659 | $14 |
| Metformin | 54 | $565 | $10 |
| Amlodipine Besylate | 47 | $531 | $11 |
| Carvedilol | 28 | $376 | $13 |
| Levothyroxine | 21 | $264 | $13 |
| Simvastatin | 26 | $239 | $9 |
| Triamcinolone Acetonide | 18 | $221 | $12 |
| Lisinopril | 20 | $184 | $9 |
| Alendronate | 13 | $127 | $10 |
| Fluoxetine | 13 | $54 | $4 |
| Omeprazole | 12 | $44 | $4 |
| Hydrochlorothiazide | 12 | $22 | $2 |
2021: 15 drugs
| Raloxifene | 14 | $1,431 | $102 |
| Losartan | 48 | $838 | $17 |
| Atorvastatin | 48 | $694 | $14 |
| Amlodipine Besylate | 74 | $639 | $9 |
| Lovastatin | 41 | $530 | $13 |
| Levothyroxine | 21 | $478 | $23 |
| Metformin | 57 | $421 | $7 |
| Carvedilol | 34 | $407 | $12 |
| Olmesartan-Hydrochlorothiazide | 12 | $366 | $31 |
| Lisinopril | 23 | $326 | $14 |
| Simvastatin | 26 | $231 | $9 |
| Triamcinolone Acetonide | 16 | $199 | $12 |
| Trazodone | 11 | $75 | $7 |
| Fluoxetine | 11 | $72 | $7 |
| Hydrochlorothiazide | 12 | $45 | $4 |
2020: 18 drugs
| Atorvastatin | 51 | $1,210 | $24 |
| Levothyroxine | 40 | $860 | $21 |
| Amlodipine Besylate | 98 | $759 | $8 |
| Albuterol Sulfate Hfa | 15 | $617 | $41 |
| Losartan | 34 | $560 | $16 |
| Lovastatin | 40 | $538 | $13 |
| Metoprolol | 15 | $475 | $32 |
| Olmesartan-Hydrochlorothiazide | 11 | $434 | $39 |
| Lisinopril | 36 | $384 | $11 |
| Metformin | 60 | $366 | $6 |
| Carvedilol | 41 | $352 | $9 |
| Simvastatin | 34 | $329 | $10 |
| Pravastatin | 11 | $311 | $28 |
| Triamcinolone Acetonide | 19 | $220 | $12 |
| Omeprazole | 26 | $155 | $6 |
| Fluoxetine | 14 | $91 | $6 |
| Escitalopram | 14 | $86 | $6 |
| Hydrochlorothiazide | 11 | $33 | $3 |
2019: 21 drugs
| Tradjenta | 16 | $10,297 | $644 |
| Atorvastatin | 79 | $1,375 | $17 |
| Amlodipine Besylate | 126 | $810 | $6 |
| Levothyroxine | 41 | $754 | $18 |
| Losartan | 38 | $568 | $15 |
| Metformin | 59 | $402 | $7 |
| Lovastatin | 33 | $385 | $12 |
| Pravastatin | 13 | $378 | $29 |
| Carvedilol | 31 | $304 | $10 |
| Simvastatin | 36 | $288 | $8 |
| Bupropion Xl | 12 | $277 | $23 |
| Lisinopril | 32 | $252 | $8 |
| Omeprazole | 18 | $147 | $8 |
| Verapamil Er | 11 | $121 | $11 |
| Amoxicillin | 14 | $107 | $8 |
| Ciprofloxacin | 16 | $101 | $6 |
| Metoprolol | 14 | $92 | $7 |
| Alendronate | 15 | $78 | $5 |
| Sertraline | 11 | $64 | $6 |
| Fluoxetine | 12 | $59 | $5 |
| Escitalopram | 12 | $55 | $5 |
2018: 21 drugs
| Tradjenta | 15 | $8,619 | $575 |
| Duloxetine | 22 | $1,577 | $72 |
| Atorvastatin | 64 | $1,359 | $21 |
| Levothyroxine | 55 | $1,100 | $20 |
| Amlodipine Besylate | 107 | $796 | $7 |
| Losartan | 53 | $759 | $14 |
| Lovastatin | 49 | $742 | $15 |
| Metformin | 59 | $440 | $7 |
| Doxycycline Hyclate | 16 | $311 | $19 |
| Simvastatin | 45 | $298 | $7 |
| Carvedilol | 42 | $287 | $7 |
| Fluoxetine | 21 | $274 | $13 |
| Quetiapine | 13 | $234 | $18 |
| Lisinopril | 28 | $229 | $8 |
| Metoprolol | 13 | $224 | $17 |
| Verapamil Er | 12 | $202 | $17 |
| Trazodone | 11 | $136 | $12 |
| Benazepril | 11 | $83 | $8 |
| Ciprofloxacin | 14 | $83 | $6 |
| Escitalopram | 12 | $56 | $5 |
| Hydrochlorothiazide | 12 | $44 | $4 |
2017: 21 drugs
| Tradjenta | 18 | $10,566 | $587 |
| Levothyroxine | 79 | $1,462 | $19 |
| Atorvastatin | 41 | $800 | $20 |
| Amlodipine Besylate | 90 | $698 | $8 |
| Lovastatin | 69 | $667 | $10 |
| Losartan | 44 | $530 | $12 |
| Fluoxetine | 25 | $338 | $14 |
| Metformin | 40 | $318 | $8 |
| Lisinopril | 37 | $306 | $8 |
| Simvastatin | 57 | $288 | $5 |
| Metoprolol | 12 | $223 | $19 |
| Quinapril | 13 | $208 | $16 |
| Omeprazole | 15 | $201 | $13 |
| Verapamil Er | 12 | $199 | $17 |
| Metoprolol | 13 | $163 | $13 |
| Carvedilol | 40 | $153 | $4 |
| Sertraline | 24 | $142 | $6 |
| Trazodone | 11 | $88 | $8 |
| Amoxicillin | 12 | $71 | $6 |
| Escitalopram | 11 | $59 | $5 |
| Hydrochlorothiazide | 11 | $41 | $4 |
2016: 22 drugs
| Tradjenta | 39 | $16,238 | $416 |
| Levothyroxine | 84 | $1,588 | $19 |
| Proair Hfa | 12 | $1,165 | $97 |
| Losartan | 71 | $747 | $11 |
| Atorvastatin | 48 | $726 | $15 |
| Lovastatin | 67 | $661 | $10 |
| Zolpidem | 13 | $612 | $47 |
| Amlodipine Besylate | 84 | $500 | $6 |
| Fluoxetine | 20 | $472 | $24 |
| Quinapril | 20 | $403 | $20 |
| Metformin | 55 | $390 | $7 |
| Metoprolol | 19 | $349 | $18 |
| Simvastatin | 72 | $342 | $5 |
| Lisinopril | 48 | $341 | $7 |
| Omeprazole | 14 | $209 | $15 |
| Hydrocodone-Acetaminophen | 12 | $172 | $14 |
| Triamcinolone Acetonide | 15 | $166 | $11 |
| Carvedilol | 29 | $165 | $6 |
| Verapamil Er | 12 | $133 | $11 |
| Sertraline | 23 | $119 | $5 |
| Hydrochlorothiazide | 11 | $50 | $5 |
| Metoprolol | 14 | $39 | $3 |
2015: 24 drugs
| Tradjenta | 40 | $14,736 | $368 |
| Levothyroxine | 71 | $1,515 | $21 |
| Fenofibrate | 18 | $1,134 | $63 |
| Zolpidem | 18 | $536 | $30 |
| Lovastatin | 51 | $478 | $9 |
| Atorvastatin | 19 | $449 | $24 |
| Nifedipine Er | 15 | $439 | $29 |
| Metformin | 69 | $425 | $6 |
| Pravastatin | 11 | $405 | $37 |
| Lisinopril | 54 | $358 | $7 |
| Simvastatin | 67 | $347 | $5 |
| Amlodipine Besylate | 58 | $339 | $6 |
| Losartan | 46 | $277 | $6 |
| Venlafaxine | 12 | $199 | $17 |
| Hydrocodone-Acetaminophen | 13 | $190 | $15 |
| Carvedilol | 32 | $152 | $5 |
| Triamterene-Hydrochlorothiazid | 13 | $144 | $11 |
| Verapamil Er | 12 | $122 | $10 |
| Triamcinolone Acetonide | 11 | $107 | $10 |
| Metoprolol | 13 | $85 | $7 |
| Hydrochlorothiazide | 18 | $69 | $4 |
| Amoxicillin | 12 | $61 | $5 |
| Atenolol | 11 | $57 | $5 |
| Glimepiride | 11 | $51 | $5 |
2014: 28 drugs
| Tradjenta | 53 | $16,284 | $307 |
| Janumet Xr | 12 | $1,786 | $149 |
| Levothyroxine | 70 | $1,354 | $19 |
| Losartan | 63 | $823 | $13 |
| Nifedipine Er | 13 | $584 | $45 |
| Lovastatin | 61 | $567 | $9 |
| Amlodipine Besylate | 53 | $511 | $10 |
| Fenofibrate | 12 | $499 | $42 |
| Metformin | 50 | $492 | $10 |
| Simvastatin | 61 | $461 | $8 |
| Lisinopril | 69 | $407 | $6 |
| Quinapril | 14 | $348 | $25 |
| Carvedilol | 37 | $322 | $9 |
| Atorvastatin | 17 | $321 | $19 |
| Venlafaxine | 12 | $304 | $25 |
| Bupropion Xl | 13 | $290 | $22 |
| Bisoprolol-Hydrochlorothiazide | 17 | $262 | $15 |
| Triamterene-Hydrochlorothiazid | 20 | $185 | $9 |
| Hydrocodone-Acetaminophen | 14 | $148 | $11 |
| Zolpidem | 19 | $118 | $6 |
| Triamcinolone Acetonide | 11 | $108 | $10 |
| Azithromycin | 11 | $88 | $8 |
| Ciprofloxacin | 15 | $74 | $5 |
| Lorazepam | 16 | $70 | $4 |
| Metoprolol | 18 | $70 | $4 |
| Hydrochlorothiazide | 22 | $66 | $3 |
| Glipizide | 17 | $65 | $4 |
| Atenolol | 12 | $59 | $5 |
2013: 24 drugs
| Tradjenta | 34 | $8,580 | $252 |
| Proair Hfa | 11 | $1,154 | $105 |
| Levothyroxine | 85 | $971 | $11 |
| Lovastatin | 77 | $910 | $12 |
| Losartan | 62 | $891 | $14 |
| Amlodipine Besylate | 70 | $571 | $8 |
| Fenofibrate | 13 | $561 | $43 |
| Simvastatin | 66 | $559 | $8 |
| Quinapril | 13 | $536 | $41 |
| Metformin | 41 | $480 | $12 |
| Lisinopril | 57 | $381 | $7 |
| Atorvastatin | 15 | $338 | $23 |
| Triamterene-Hctz | 23 | $284 | $12 |
| Fluticasone Propionate | 12 | $274 | $23 |
| Verapamil Er | 11 | $270 | $25 |
| Bisoprolol-Hydrochlorothiazide | 13 | $208 | $16 |
| Hydrocodone-Acetaminophen | 28 | $187 | $7 |
| Carvedilol | 18 | $142 | $8 |
| Metoprolol | 15 | $124 | $8 |
| Alendronate | 16 | $119 | $7 |
| Hydrochlorothiazide | 35 | $105 | $3 |
| Zolpidem | 18 | $105 | $6 |
| Atenolol | 13 | $98 | $8 |
| Ciprofloxacin | 11 | $64 | $6 |
Money from drug and device companies
$781 in 2025
| 2025 | 11 | 31 | None | $781 |
| 2024 | 6 | 19 | None | $470 |
| 2023 | 8 | 15 | None | $368 |
| 2022 | 6 | 9 | None | $209 |
| 2021 | 1 | 1 | None | $27 |
| 2020 | 1 | 1 | None | $15 |
| 2019 | 15 | 32 | None | $718 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | Wegovy | $169 | 7 payments
|
| Pfizer | Nurtec Odt | $141 | 5 payments
|
| GlaxoSmithKline | Shingrix | $95 | 4 payments
|
| Gilead Sciences | Yeztugo | $88 | 3 payments
|
| Abbvie | Qulipta | $77 | 4 payments
|
| Lilly USA | Mounjaro | $55 | 2 payments
|
See all 31 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-09 | Breztri | $22 |
| Pfizer | Meals · 2025-11-26 | Eliquis | $31 |
| Astellas Pharma US | Meals · 2025-11-25 | Veozah | $28 |
| Pfizer | Meals · 2025-11-18 | Nurtec Odt | $22 |
| Novo Nordisk | Meals · 2025-11-05 | Rybelsus | $23 |
| GlaxoSmithKline | Meals · 2025-10-27 | Shingrix | $15 |
| Abbvie | Meals · 2025-10-23 | Qulipta | $16 |
| Pfizer | Meals · 2025-10-03 | Nurtec Odt | $25 |
| Gilead Sciences | Meals · 2025-09-17 | None | $34 |
| Lilly USA | Meals · 2025-09-12 | Mounjaro | $32 |
| Abbvie | Meals · 2025-09-03 | Qulipta | $24 |
| Novo Nordisk | Meals · 2025-08-30 | Wegovy | $22 |
| Gilead Sciences | Meals · 2025-08-25 | None | $27 |
| Dexcom | Meals · 2025-08-22 | Dexcom G6 Transmitter | $27 |
| Abbvie | Meals · 2025-08-08 | Ubrelvy | $13 |
| Novo Nordisk | Meals · 2025-07-31 | Rybelsus | $25 |
| Gilead Sciences | Meals · 2025-07-09 | Yeztugo | $27 |
| Lilly USA | Meals · 2025-06-11 | Mounjaro | $23 |
| Novo Nordisk | Meals · 2025-06-07 | Wegovy | $21 |
| Novo Nordisk | Meals · 2025-05-17 | Ozempic | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-14 | Wainua | $20 |
| GlaxoSmithKline | Meals · 2025-05-09 | Shingrix | $22 |
| Abbvie | Meals · 2025-05-07 | Qulipta | $24 |
| Pfizer | Meals · 2025-04-25 | Nurtec Odt | $25 |
| Novo Nordisk | Meals · 2025-04-22 | None | $27 |
| Exact Sciences | Meals · 2025-03-12 | Cologuard Collection Kit | $20 |
| GlaxoSmithKline | Meals · 2025-02-28 | Shingrix | $29 |
| GlaxoSmithKline | Meals · 2025-02-14 | Trelegy Ellipta | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-12 | Eliquis | $38 |
| Novo Nordisk | Meals · 2025-01-18 | Wegovy | $21 |
| Pfizer | Meals · 2025-01-07 | Eliquis | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $470
| Abbvie | Qulipta | $189 | 7 payments
|
| Novo Nordisk | Ozempic | $113 | 5 payments
|
| Pfizer | Eliquis | $58 | 2 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $47 | 2 payments
|
| Lilly USA | Mounjaro | $44 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $19 | 1 payment
|
2023: $368
| E.R. Squibb & Sons L.L.C. | Camzyos | $70 | 2 payments
|
| Novo Nordisk | Rybelsus | $66 | 3 payments
|
| Amgen | Evenity | $56 | 2 payments
|
| Pfizer | Paxlovid | $46 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $46 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $39 | 2 payments
|
| Bausch Health US | Aplenzin | $25 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $20 | 1 payment
|
2022: $209
| E.R. Squibb & Sons L.L.C. | Eliquis | $59 | 3 payments
|
| Abbvie | Ubrelvy | $49 | 2 payments
|
| Amgen | Evenity | $31 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $26 | 1 payment
|
| Bausch Health US | Aplenzin | $26 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $19 | 1 payment
|
2021: $27
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $27 | 1 payment
|
2020: $15
| Amgen | Evenity | $15 | 1 payment
|
2019: $718
| GlaxoSmithKline | Trelegy Ellipta | $153 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Tradjenta | $109 | 4 payments
|
| Regeneron Healthcare Solutions | Praluent | $86 | 3 payments
|
| Gilead Sciences | None | $61 | 3 payments
|
| Merck Sharp & Dohme | Januvia | $47 | 3 payments
|
| Amgen | Prolia | $45 | 2 payments
|
| Novo Nordisk | Ozempic | $44 | 2 payments
|
| AbbVie | Creon | $41 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $23 | 1 payment
|
| Sanofi-Aventis U.S. | Praluent | $20 | 1 payment
|
| Pfizer | Prevnar - 13 | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $19 | 1 payment
|
| Lilly USA | Glyxambi | $18 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $17 | 1 payment
|
| Mannkind | Afrezza | $16 | 1 payment
|
Professional record
- NPI
- 1386783033
- Licence
- CA A053244
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 1 Shrader St Ste 500, San Francisco, CA, 94117
- NPI first listed
- 2007-02-06
- NPI last updated
- 2026-02-10
- NPI record certified
- 2026-02-10
This is when the NPI record was last certified, not a medical board exam.